These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 17180769

  • 1. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
    Steinhauer EH.
    Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
    [No Abstract] [Full Text] [Related]

  • 2. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV.
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract] [Full Text] [Related]

  • 3. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS.
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract] [Full Text] [Related]

  • 4. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA.
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract] [Full Text] [Related]

  • 5. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA.
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [Abstract] [Full Text] [Related]

  • 6. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM.
    Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract] [Full Text] [Related]

  • 7. Bundling patented drugs and medical services: an antitrust analysis.
    Hurwitz MA.
    Spec Law Dig Health Care Law; 1992 Jan; (155):7-39. PubMed ID: 10115664
    [No Abstract] [Full Text] [Related]

  • 8. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z.
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract] [Full Text] [Related]

  • 9. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC.
    Food Drug Law J; 2004 Jul; 59(1):155-68. PubMed ID: 15190929
    [No Abstract] [Full Text] [Related]

  • 10. The Hatch-Waxman Act: balancing competing interests or survival of the fittest?
    Behrendt KE.
    Food Drug Law J; 2002 Jul; 57(2):247-71. PubMed ID: 12436990
    [No Abstract] [Full Text] [Related]

  • 11. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003 Jul; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

  • 12. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
    Leary TB.
    J Health Law; 2001 Jul; 34(4):657-71. PubMed ID: 11833411
    [Abstract] [Full Text] [Related]

  • 13. Navigating the Hatch-Waxman Act's safe harbor.
    Jones PB.
    Food Drug Law J; 2002 Jul; 57(3):475-89. PubMed ID: 12710407
    [No Abstract] [Full Text] [Related]

  • 14. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
    Deal JB.
    Food Drug Law J; 1999 Jul; 54(2):185-6. PubMed ID: 11759712
    [No Abstract] [Full Text] [Related]

  • 15. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM.
    Seton Hall Law Rev; 2011 Jul; 41(2):559-92. PubMed ID: 21739759
    [No Abstract] [Full Text] [Related]

  • 16. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE.
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract] [Full Text] [Related]

  • 17. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS.
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract] [Full Text] [Related]

  • 18. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS.
    Food Drug Law J; 1999 Mar; 54(2):223-5. PubMed ID: 11759713
    [No Abstract] [Full Text] [Related]

  • 19. Correcting Hatch-Waxman.
    Fernandes M.
    Health Aff (Millwood); 2008 Mar; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract] [Full Text] [Related]

  • 20. The application of the patent laws to the drug approval process.
    Coggio BD, Cerrito FD.
    Food Drug Law J; 1997 Mar; 52(4):345-55. PubMed ID: 10346669
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.